Bromocriptine augmentation therapy in a patient with Cotard's syndrome

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 4, 2003, Pages 719-721

  Kondo, Shuko ^a   Hayashi, Hiroshi ^a   Eguchi, Takuya ^b   Oyama, Takanobu ^b   Wada, Tadashi ^c   Otani, Koichi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b Nihonmatsu kai Kaminoyama Hospital   (Japan)

^c Wada Clinic   (Japan)

Author keywords

Augmentation therapy; Bromocriptine; Cotard's syndrome; Mood disorders

Indexed keywords

ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CLOMIPRAMINE; LITHIUM; NEUROLEPTIC AGENT;

AGED; ARTICLE; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; COTARD SYNDROME; DELUSION; DEPRESSION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; SUICIDE; SYNDROME;

EID: 0037674661     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00083-6     Document Type: Article

References (13)

1. Austin M.P., Souza F.G., Goodwin G.M. Lithium augmentation in antidepressant-resistant patients: a quantitative analysis. Br. J. Psychiatry. 159:1991;510-514.
2. Baeza I., Salva J., Bernardo M. Cotard's syndrome in a young male bipolar patient. J. Neuropsychiatry Clin. Neurosci. 12:2000;119-120.
3. Berrios G.E., Luque R. Cotard's syndrome: analysis of 100 cases. Acta Psychiatr. Scand. 91:1995;185-188.
4. Cohen D., Cottias C., Basquin M. Cotard's syndrome in a 15-year-old girl. Acta Psychiatr. Scand. 95:1997;164-165.
5. Fuxe K., Fredholm B.B., Ogren S.O., Agnati L.F., Hokfelt T., Gustafsson J.A. Pharmacological and biochemical evidence for the dopamine agonistic effect of bromocriptine. Acta Endocrinol. 78(Suppl. 216):1978;27-56.
6. Inoue T., Tsuchiya K., Miura J., Sakakibara S., Denda K., Kasahara T., Koyama T. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol. Psychiatry. 40:1996;151-153.
7. Joffe R.T., Levitt A.J., Bagby R.M., Macdonald C., Singer W. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br. J. Psychiatry. 163:1993;574-578.
8. Montastruc J.L., Rascol O., Senard J.M. Current status of dopamine agonists in Parkinson's disease management. Drugs. 46:1993;384-393.
9. Nielsen K.A., Flinois J.P., Beaune P., Brosen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J. Pharmacol. Exp. Ther. 277:1996;1659-1664.
10. Wada T., Kanno M., Aoshima T., Otani K. Dose-dependent augmentation effect of bromocriptine in a case with refractory depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 25:2001;457-462.
11. Wheeler Vega J.A., Mortimer A.M., Tyson P.J. Somatic treatment of psychotic depression: review and recommendations for practice. J. Clin. Psychopharmacol. 20:2000;504-519.
12. Wynalda M.A., Wienkers L.C. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab. Dispos. 25:1997;1211-1214.
13. Yamada K., Katsuragi S., Fujii I. A case of Cotard's syndrome: stages and diagnosis. Acta Psychiatr. Scand. 100:1999;396-399.